InMed Pharmaceuticals Amends Deal With Mentari Therapeutics
InMed Pharmaceuticals (INM) entered into an amendment to its definitive merger agreement for an all-stock transaction with Mentari Therapeutics and its subsidiaries that clarifies details of the deal, the company said Monday. The updated details include the sequencing of the acquisition, the impact of the pre-closing financing on the exchange ratio, and the intended tax treatment of the merger, the company said. The merger has received approval by the boards of both companies in Q4 2026, the company said.
InMed Pharmaceuticals (INM) entered into an amendment to its definitive merger agreement for an all-stock transaction with Mentari Therapeutics and its subsidiaries that clarifies details of the deal, the company said Monday.
The updated details include the sequencing of the acquisition, the impact of the pre-closing financing on the exchange ratio, and the intended tax treatment of the merger, the company said.
The merger has received approval by the boards of both companies in Q4 2026, the company said.